PDF hosted at the Radboud Repository of the Radboud University Nijmegen

Similar documents
Port-Site Metastases After Robotic Surgery for Gynecologic Malignancy

Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer

Clinical Study Laparoscopic Surgery in Elderly Patients Aged 65 Years and Older with Gynecologic Disease

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Prof. Dr. Aydın ÖZSARAN

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary

Hitting the High Points Gynecologic Oncology Review

INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for

Implementation of laparoscopic surgery for endometrial cancer: work in progress

ISPUB.COM. S Kumar, A Gupta, S Gupta, M Jaura INTRODUCTION MATERIAL AND METHODS

H&E, IHC anti- Cytokeratin

Staging and Treatment Update for Gynecologic Malignancies

An Example of Business Analytics in Healthcare

Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer

Guideline for the Management of Vulval Cancer

Chapter 8 Adenocarcinoma

Consent Advice No. XX (Joint with BSGE) Peer Review Draft Spring Morcellation for Laparoscopic Myomectomy or Hysterectomy

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

Surveillance report Published: 17 March 2016 nice.org.uk

Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy

Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma

Gestione dei tumori borderline iniziali e avanzati nelle donne in età fertile

Role of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters

Epithelial Ovarian Cancer

Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122

Borderline Ovarian Tumours. Andreas Obermair Brisbane

BACKGROUND. The objective of this study was to determine the impact of malignant

Case Report Serous Ovarian Carcinoma Recurring as Malignant Mixed Mullerian Tumor

Index. B Bilateral salpingo-oophorectomy (BSO), 69

ISUOG Basic Training Typical Ultrasound Appearances of Common Pathologies in the Adnexae

Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran

Gynaecological Pathology Reporting. Peritoneal cytology Tony Williams Birmingham

Appendix cancer mimicking ovarian cancer

David Nunns on behalf of the Gynae Guidelines Group Date:

Interactive Staging Bee

PET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp

Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013

Institute of Pathology First Faculty of Medicine Charles University. Ovary

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer

Gynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer

Clinical statistics of gynecologic cancers in Japan

Research Article Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer

SURGICAL MANAGEMENT OF EPITHELIAL OVARIAN CANCER PARSGO, MARRAKECH 2018

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the

Carcinoma of the Fallopian Tube

Primary Fallopian Tube Cancer : A Rare Gynecological Malignancy

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

NAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary

receive adjuvant chemotherapy

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology

LAPAROSCOPY and OVARIAN CANCER

Citation for published version (APA): Bartels, S. A. L. (2013). Laparoscopic colorectal surgery: beyond the short-term effects

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

FDG-PET/CT in Gynaecologic Cancers

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

Case Report Laparoscopic Diagnosis of Adenocarcinoma of the Appendix Mimicking Serous Papillary Adenocarcinoma of the Peritoneum

Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei

HE4 Human Epididymal Protein 4 A novel oncological biomarker improving ovarian cancer care

Management of Neck Metastasis from Unknown Primary

Morphological effects of chemotherapy on ovarian carcinoma

Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV

Tissue Morcellation: Managing Risks to Drive Best Patient Outcomes

Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases

The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients ( 40 years old) with borderline ovarian tumors

2007 Cancer Committee

International Society of Gynecological Pathologists Symposium 2007

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

Stage 3 ovarian cancer survival rate

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Current Concept in Ovarian Carcinoma: Pathology Perspectives

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

Ovarian Cancer Audit Comparative Annual Report 01/01/ /12/2009

Diagnostic accuracy of ultrasonography with color doppler imaging techniques in adnexal masses and correlation with histopathological analysis

Laparoscopy in the Treatment of Early Cervical Carcinoma

Stage 3 ovarian cancer survival rate

UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS

HYSTERECTOMY FOR BENIGN CONDITIONS

Metastatic mechanism of spermatic cord tumor from stomach cancer

Gynaecological Oncology Cases

How to Define, Evaluate, and Identify Surgical Quality. Viewpoint of the ESGO Quality Assurance Committee

Laparoscopic Resection Of Colon & Rectal Cancers. R Sim Centre for Advanced Laparoscopic Surgery, TTSH

Endometriosis of the Appendix Resulting in Perforated Appendicitis

Ovarian Cancer Quality Performance Indicators

Adjuvant treatment, tumour recurrence and the survival rate of uterine serous carcinomas: a single-institution review of 62 women

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin

Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients

See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done.

Ovarian cancer antigen CA125: A prospective clinical

GENERAL DATA. Sex : female Age : 40 years old Marriage status : married

surgical staging g in early endometrial cancer

Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer

7. Cytoreductive surgery in endometrial cancer and uterine sarcomas

Fast Facts: Ovarian Cancer

Study of ascitic fluid cytology in ovarian tumors

CONTRIBUTION. Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma

Transcription:

PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096 Please be advised that this information was generated on 2018-07-07 and may be subject to change.

GYNECOLOGIC ONCOLOGY 60, 233-237 (1996) ARTICLE NO. 0031 Incidence and Effect on Survival of Abdominal Wall Métastasés at Trocar or Puncture Sites Following Laparoscopy or Paracentesis in Women with Ovarian Cancer R. F. P. M. K r u it w a g e n,* '1 B. M. S w in k e ls,1 ' K. G. G. K e y s e r,! W. H. D o e s b u r g,! a n d Ch. P. Th. ScHiJFf * Department of Obstetrics and Gynecology, Bosch Medical Center, P.O. 90153, 5200 ME s-hertogenbosch, The Netherlands; and f Department of Obstetrics and Gynecology and -tdepartment of Medical Statistics, Academic University, Nijmegen, The Netherlands Received March 16, 1995 MATERIALS AND METHODS The aim of this retrospective study was to examine the incidence and prognostic significance of abdominal wall metastases in patients with ovarian cancer present at the primary debulking at the entry sites of previous laparoscopy or paracentesis. The clinical records of 219 patients were studied. In 7 of 43 patients (16%) who had undergone laparoscopy and 3 of 30 patients (10%) who had undergone paracentesis previous to the primary debulking, an abdominal wall metastasis had developed at the entry sites. All metastases occurred in patients with FIGO stage IIIC - IV including ascites. Survival analysis using the Cox proportional hazards model showed that after adjustment for age, FIGO stage3 histology, grade, ascites, and residual disease after primary debulking, the presence of abdominal wall metastases in the entry sites of previous laparoscopy or paracentesis was negatively, although not statistical significantly, correlated with survival (P = 0.14). 1996 Academic Press, Inc. The case records of 419 patients with ovarian cancer diagnosed between 1979 and 1991 in the University Hospital Nijmegen and the Bosch Medical Center at s-hertogenbosch were scrutinized. The year 1979 was chosen because from that year onward cisplatin was common as part of the adjuvant chemotherapy. Only those patients with epithelial ovarian cancer and no previous therapy were included in the study (n = 219). They were staged according to the revised FIGO classification of 1987 [6]. Patient's age and tumor characteristics are summarized in Table 1, Abdominal wall metastases at the laparoscopic trocar or paracentesis sites had to comply with the following criteria: (1) presence at the primary debulking, (2) subcutaneous, and (3) histologically confirmed. All abdominal wall metastases were removed during the primary debulking. The survival time was calculated from the date of the primary debulking. INTRODUCTION All laparoscopies were performed using the double-puncture technique. After making a (sub)umbilical incision (1 Both laparoscopy and paracentesis are known procedures in the diagnosis of abdominal malignancy including ovarian cancer. Numerous case reports have described the development of tumor implants occurring at the abdominal trocar entry sites after laparoscopy in patients with ovarian cancer [1-5], Nevertheless, some of these reports have stated that the development of such tumor implants after laparoscopy in patients with ovarian carcinoma is rare [I, 2]. So far, to our knowledge, no systematic study has been performed regarding its incidence and possible prognostic significance. This retrospective study was performed to determine the incidence of abdominal wall metastases at trocar or puncture entry sites after laparoscopy or paracentesis, and whether it influences survival. cm), a Verres needle was inserted and a pneumoperitoneum was established by insufflating carbon dioxide to an intraabdominal pressure of 10 mm Hg. After removing the Verres needle a 10-mm trocar was placed through the (sub)umbilical incision. The laparoscope was introduced through this trocar and used to transilluminate the site of the second port. This second S-mm trocar was introduced at either the midline or lower right quadrant of the abdomen. Paracenteses were not routinely performed with ultrasonic guidance. Cox s proportional hazards model was used to quantify the effect of the presence of the abdominal wall metastases at the entry sites of previous laparoscopy or paracentesis on survival, taking account of known prognostic factors (age, FIGO stage, histology, grade, residual disease after primary debulking, and the presence or absence of ascites). The performance status could not be introduced as a variable with 1To whom correspondence should be addressed. possible effect on survival because the performance status «233 0090-8258/96 $18.00 Copyright 1996 by Academic Press, Inc. A ll rights o f reproduction in any form reserved.

234 «TABLE 1 KRUITW AGEN ET AL. Age and Tumor Characteristics of the 219 Patients Age (years) patients (% ) ^ 4 4 35 (16.0) 45-54 47 (21.5) 55-64 60 (27.4) 65-74 63 (28.7) ^7 5 14 (6.4) FIG O stage I 52 (237) II 35 (16.0) III 103 (47.0) IV 29 (13.3) Grade I 22 ( 12.2) II 64 (35.4) III 90 (49.7) Undifferentiated 5 (2.7) Unknown 38 Histology Serous 84 (38.4) Mucinous 43 (19.6) Endometrioid 31 (14.2) Cystadenocarcinoma 39 (17.8) Clear cell 7 (3.2) Malignant Brenner 4 (1.8) Mixed 6 (2.7) Undifferentiated 5 (2.3) Ascites No 105 (48.4) Yes 112 (51.6) Unknown 2 Residual disease after primary debulking None (macroscopic) 74 (40.6) <2 cm 46 (25.3) >2 cm 62 (34.1) Unknown 37 Abdominal wall metastases No previous laparoscopy or paracentesis No 144 (96.0) Yes 6 (4.0) Previous laparoscopy or paracentesis No 57 (82.6) Yes, at trocar or puncture entry site 10 (14.5) Yes, not at trocar or puncture entry sites 2 (2.9) was not systematically registered in the case records. First, the likelihood-ratio test (LR test) was applied to investigate the influence of each of the above-mentioned factors on survival. Second, the effect on survival of abdominal wall metastases was evaluated after adjustment for all other factors. The variable age was divided into five subgroups of patients (^4 4, 45-54, 55-64, 65-74, and 5=75 years). The variable histology was reduced to two subgroups (serous/ mucinous/endometrioid/not classified cystadenocarcinoma and clear cell/malignant Brenner/mixed/undifferentiated). The variable residual disease after primary debulking was divided into three types (no macroscopic residual disease, residual disease ^ 2 cm, and residual disease >2 cm). The variable abdominal wall metastases was divided into three types (no abdominal wall metastases, abdominal wall métastasés not related to entry sites of previous laparoscopy or paracentesis, and abdominal wall metastases at entry sites of previous laparoscopy or paracentesis). The amount of fluid that constitutes ascites was defined as 100 ml or more. RESULTS» in 7 of 43 patients (16%) in whom a diagnostic laparoscopy was performed preceding the primary debulking, one or more abdominal wall metastases developed at the entry sites (five patients had a metastasis at one, two patients had metastases at two entry sites). In 3 of 30 patients (10%) in whom one (n 25) or more (n = 5) paracenteses were performed preceding the primary debulking, an abdominal wall metastasis developed at the entry site. In these three patients only one paracentesis was performed. In none of the laparoscopic procedures and paracenteses were difficulties and/or complications reported. All 10 patients with abdominal wall metastases at the entry sites of the laparoscopic trocars or paracentesis had the following features in common: FIGO stage IIIC or IV ; grade II, III, or unknown ; and ascites present at the primary debulking. None of the women without ascites (n 21) and/or stage I-II disease (n = 14) developed abdominal wall metastases following laparoscopy or paracentesis. The median time interval between the laparoscopy or paracentesis and primary debulking was 15 days in the 10 patients who had developed abdominal wall metastases at the trocar entry sites (range, 9-35 days) and 13 days in the 63 patients who had not developed abdominal wall metastases after previous laparoscopy or paracentesis (range, 1-187 days); the difference was not statistically significant. Eight patients had abdominal, wall metastases present at the primary debulking not related to a previous laparoscopy or paracentesis (Table 1). The survival time was significantly related to age, FIGO stage, tumor grade, residual disease after primary debulking, ascites, and abdominal wall metastases at the entry sites of previous laparoscopy or paracentesis (Table 2). No significant correlation was found with tumor histology. In the Cox proportional hazards model, patients with abdominal wall metastases at the entry sites adjusted for age, FIGO stage, grade, histology, ascites, and residual disease after primary debulking had a shorter survival time, although the difference was not statistically significant (Table 3). For example, patients with abdominal wall metastases at the entry sites of previous laparoscopy or paracentesis together with the combination of age of 65-74 years, grade III cystadenocarci-

TUMOR IMPLANTS AFTER LAPAROSCOPY OR PARACENTESIS 235 TABLE 2 Relation between Factors and Survival among 219 Ovarian Cancer Patients, Diagnosed between 1979 and 1991 Factor patients deaths in 3 years (% )a Relative hazard with respect to baseline 95% confidence interval for relative hazard P value Age group 35 6 (17) L 00 Baseline < 0.001 45-54 47 18 (38) 2.02 0.96-4.26 VI 55-64 60 29 (48) 2.56 1.26-5.19 65-74 63 35 (56) 3.56 1.79-7.10 2:75 Í4 11 (79) 9.70 4.07-23.13 FIGO stage I 52 5 (10) 1.00 Baseline < 0.001 II 35 5 (14) 1.68 0.67-4.26 III 103 65 (63) 9.19 4.55-18.57 IV 29 24 (83) 23.63 10.64-52.48 Grade I 22 3 (14) 1.00 Baseline < 0.001 II 64 24 (38) 3.12 1.2 2-7.98 III + undifferentiated 95 55 (58) 5.27 2. 1 1-13.17 Histology Cystadenocarcinoma 197 86 (44) 1.00 Baseline 0.70 Others 22 13 (59) 1.12 0.63-1.99 Ascites No 105 25 (24) 1.00 Baseline < 0.001 Yes 112 74 (6 6) 4.31 2.88-6.46 Residual disease after debuiking None (macroscopic) 74 10 (14) 1.00 Baseline < 0.001 ^ 2 cm 46 29 (63) 5.72 3.17-10.30 > 2 cm 62 45 (73) 8.23 4.70-14.41 Abdominal wall metastases No 201 85 (42) LOO Baseline < 0.001 Yes, not at entry sites 8 5 (63) 2.39 1.05-5.48 Yes, at entry site 10 9 (90) 5.12 2.65-9.89 All of the deaths were due to cancer progression. noma FIGO stage III, residual disease > 2 cm, and ascites present had a much worse survival than patients with the same combination but without abdominal wall métastasés in the entry sites (Table 4). D ISC U SSIO N Laparoscopy is a common procedure in the diagnostic workup of possibly gynecological related complaints. Also TABLE 3 Relation between Abdominal Wall Metastases and Survival after Adjustment for the Known Risk Factors: Age, FIGO Stage, Tumor Grade, Histology, Ascites, and Residual Disease patients deaths in 3 years (%)a Risk Ratio 95% confidence interval P value Abdominal wall metastases No 137 63 (46) 1.00 Baseline 0.14 Yes, not at entry sites 6 4(6 7 ) 1.10 0.38-3.22 Yest at entry site 7 6 (86) 2.70 1.08-6.75 Unknown for at least one factor 69 " All of the deaths were due to cancer progression.

236 KRUITWAGEN ET AL. TABLE 4 Survival (Calculated within the Cox s Proportional Hazards Model. All Patients 65-74 Years of Age, FIGO III, Cystadenocarcinoma, Tumor Grade III, Residual Disease >2 cm, and Ascites Present) Survival period in months No abdominal wall metastases (%) Abdominal wall metastases outside trocar or puncture entry sites (%) Abdominal wall metastases at trocar or puncture entry site (%) 3 92 91 79 6 85 84 65 12 64 61 30 18 46 42 12 24 31 28 4 in cases in which an ovarian malignancy is suspected, a laparoscopy can be performed to confirm the diagnosis. In the presence of ascites a paracentesis with cytological examination of the fluid obtained can attribute to the diagnosis. Numerous case reports have mentioned the development of tumor metastases at entry sites after a diagnostic laparoscopy in patients with ovarian cancer. In reports on patients with advanced disease [1, 2], and also in patients with ovarian tumors of low malignant potential [3, 5], metastases in the abdominal wall after a diagnostic laparoscopy have been described. Childers et a l [7] recently reviewed 88 diagnostic laparoscopic procedures in which an intraperitoneal malignancy was documented, of which 88% (77/88) had gross disease and 80% (70/88) had ovarian cancer. In only one case, in which microscopical ovarian cancer disease was present, a tumor metastasis developed at the abdominal wall puncture site. It was stated therefore that such tumor implantation after laparoscopy is an infrequent occurrence. In the present study, in 43 of 219 patients (19.7%) a diagnostic laparoscopy preceded the primary debulking of an ovarian carcinoma. Furthermore, in 30 patients (13.7%) a paracentesis was performed preceding the primary debulking. In 10 of these 73 patients (13.7%) abdominal wall tumor implantation occurred at these trocar or puncture sites. This is a much higher percentage than that reported by Childers et al [7]. The reason(s) for this discrepancy is not known. The occurrence of abdominal wall metastases after laparoscopy or paracentesis was reportedly only in patients with FIGO stage IIIC - IV including the presence of ascites. None of the women without ascites and/or stage I II disease abdominal wall metastases developed in the interval between laparoscopy or paracentesis and laparotomy. Nduka et al [8], in a review, mentions numerous aspects specifically related to laparoscopy which may lead to an increased likelihood of wound metastases. The present data support the concept that the presence and possibly leakage of ascites through the small skin incision is one of the mechanisms resulting in an increased contamination of these skin incisions with malignant cells. A negative correlation was found between the development of these metastases and duration of survival independent of known prognostic factors such as age, FIGO stage, grade, histology, residual disease after primary debulking, and the presence or absence of ascites. This negative correlation was not statistically significant, possibly due to the small samples. It is plausible that in cases of stage III IV ovarian carcinoma, the development of abdominal wall metastases at the entry sites after laparoscopy or paracenteses itself does not affect survival, but rather it is the expression of the biological aggressiveness of the tumor which in turn explains the shorter survival. In addition to diagnostic laparoscopic procedures, laparoscopic surgery is becoming more widely used in the treatment of adnexal masses considered as being benign. Maiman et al [9] found that 31 % of laparoscopically removed ovarian tumors considered to be benign were subsequently found to be malignant. Recently, the development of an abdominal wall metastasis after laparoscopic removal of a borderline ovarian tumor has been described [10]. Therefore, it is important that also in cases in which an ovarian tumor is considered to be benign and is laparoscopically removed, one should try to minimize the exposure of the small incisions to exfoliated cells [8]. This can be accomplished by leaving the ovarian tumor intact until it is resected and placed in a pouch in which it can be aspirated if necessary and finally removed through the skin incision. In conclusion, in cases of pelvic masses in which an ovarian malignancy is supected, one should be reserved in performing a laparoscopy or paracentesis. The development of abdominal wall metastases in these cases at the entry sites of previous laparoscopy or paracentesis is a grave prognostic sign. During laparoscopic surgery one should always try to minimize the exposure of the small skin incisions to exfoliated cells. REFERENCES 1. Dbbronte, Z., Wittmann, T., and Karacsony, G. Rapid development of malignant metastases in the abdominal wall after laparoscopy, Endoscopy 10, 127-30 (1978).

TUMOR IMPLANTS AFTER LA PA RO SC O PY O R PARACENTESIS 237 2. Stockdale, A. D., and Pocock, T. J. Abdominal wall metastasis following laparoscopy: A case report, Eur. J. Surg. O ncol. 11, 373-375 (1985). 3. Hsiu, J. G,, Given, F. T., and Kemp, G. M. Tumor implantation after diagnostic laparoscopic biopsy of serous ovarian tumors of low malignant potential, Obstet. Gynecol. 68S, 90-93 (1986). 4. Miralles, R. M., Petit, J., Giné, L., and Balaguero, L. Metastatic cancer spread at the laparoscopic puncture site: Report of a case in a patient with carcinoma of the ovary, Eur. J. Gynaecol O n co l 10, 442 444 (1989). 5. Gleeson, N. C., Nicosia, S. V., Mark, J. E., Hoffman, M. S., and Cavanagh, D. Abdominal wall metastases from ovarian cancer after laparoscopy, Am. J. Obstet. Gynecol. 169, 522-523 (1993). 6. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma o f the cervix and ovary, Am. J. Obstet Gynecol. 156, 263-264 (1987). 7. Childers, J. M., Aqua, K. A., Surwit, E. A., Hallum, A. V., and Hatch, K. D. Abdominal-wall tumor implantation following laparoscopy for malignant conditions, in Abstracts Western A ssociation o f Gynaecological Oncologists, Vol. 18, p. 108 (1994). 8. Nduka, C. C., Monson, J. R. T., Menzies-Gow, N., and D am, A. Abdominal wall metastases following laparoscopy, Br. J. Surg. 81, 648-652 (1994). 9. Maimann, M., Seltzer, V., and Boyce, J. Laparoscopic excision of ovarian neoplasms subsequently found to be malignant, Obstet. Gynaecol, 77, 563-565 (1991). 10. Shepherd, J. H., and Carter, P. G. Wound recurrence by implantation of a borderline ovarian tumour following laparoscopic removal, Br. J. Obstet. Gynaecol. 101, 265-266 (1994). t ft 1